tbuckley/cabot-search huggingface dataset:
Decline in eGFR in HCV-infected patients while on treatment with sofosbuvir/ledipasvir or PrOD regimens is not dependent on baseline eGFR
Authors: M. Alkadi, Y. Ren, A.-B. Abou-Samra, A. Puenpatom, J.M. Arduino, R. Kumar, A.A. Butt
Journal: Journal of Hepatology (2017)
MELD score &gt;19 on day five after liver transplant in hepatitis C virus-positive recipients: impact on 90-day graft loss and analysis of predictors
Authors: S. Martini, F. Tandoi, L.T. di Bergamo, S. Strona, M. Sacco, F. Maione, F. Gonella, M. Salizzoni, G.M. Saracco, R. Romagnoli
Journal: Journal of Hepatology (2017)
Immunisation Information Systems – useful tools for monitoring vaccination programmes in EU/EEA countries, 2016
Authors: Tarik Derrough, Kate Olsson, Vincenza Gianfredi, Francois Simondon, Harald Heijbel, Niklas Danielsson, Piotr Kramarz, Lucia Pastore-Celentano
Journal: Eurosurveillance (2017)

Immunisation Information Systems (IIS) are computerised confidential population based-systems containing individual-level information on vaccines received in a given area. They benefit individuals directly by ensuring vaccination according to the schedule and they provide information to vaccine providers and public health authorities responsible for the delivery and monitoring of an immunisation programme. In 2016, the European Centre for Disease Prevention and Control (ECDC) conducted a survey on the level of implementation and functionalities of IIS in 30 European Union/European Economic Area (EU/EEA) countries. It explored the governance and financial support for the systems, IIS software, system characteristics in terms of population, identification of immunisation recipients, vaccinations received, and integration with other health record systems, the use of the systems for surveillance and programme management as well as the challenges involved with implementation. The survey was answered by 27 of the 30 EU/EEA countries having either a system in production at national or subnational levels (n = 16), or being piloted (n = 5) or with plans for setting up a system in the future (n = 6). The results demonstrate the added-value of IIS in a number of areas of vaccination programme monitoring such as monitoring vaccine coverage at local geographical levels, linking individual immunisation history with health outcome data for safety investigations, monitoring vaccine effectiveness and failures and as an educational tool for both vaccine providers and vaccine recipients. IIS represent a significant way forward for life-long vaccination programme monitoring.
Bacterial infections in cirrhosis – a retrospective analysis updating on microbiology and resistance rates
Authors: T. Bucsics, M. Emich, E. Berger, M.C. Nackenhorst, P. Schwabl, M. Mandorfer, B. Scheiner, M. Trauner, A. Ferlitsch, T. Reiberger
Journal: Journal of Hepatology (2017)
Approach to investigation and treatment of persistent symptoms following sport-related concussion: a systematic review
Authors: Michael Makdissi, Kathryn J Schneider, Nina Feddermann-Demont, Kevin M Guskiewicz, Sidney Hinds, John J Leddy, Michael McCrea, Michael Turner, Karen M Johnston
Journal: British Journal of Sports Medicine (2017)

<h3>Objective</h3> To conduct a systematic review of the literature regarding assessment and treatment modalities in patients with persistent symptoms following sport-related concussion (SRC). <h3>Data sources</h3> We searched Medline, Embase, SPORTSDiscus, PsycINFO, CINAHL, Cochrane library and ProQuest Dissertation &amp; Theses Global electronic databases. <h3>Study eligibility criteria</h3> Studies were included if they were original research, reported on SRC as the primary source of injury, included patients with persistent postconcussive symptoms (&gt;10 days) and investigated the role of assessment or treatment modalities. <h3>Results</h3> Of 3225 articles identified in the preliminary search, 25 articles met the inclusion criteria. 11 articles were concerned with assessment and 14 articles with treatment of persistent symptoms following SRC. There were three randomised control trials and one quasi-experimental study. The remainder consisting of cross-sectional studies, historical cohorts and case series. <h3>Summary</h3> ‘Persistent symptoms’ following SRC can be defined as clinical recovery that falls outside expected time frames (ie, &gt;10–14 days in adults and &gt;4 weeks in children). It does not reflect a single pathophysiological entity, but describes a constellation of non-specific post-traumatic symptoms that may be linked to coexisting and/or confounding pathologies. A detailed multimodal clinical assessment is required to identify specific primary and secondary processes, and treatment should target specific pathologies identified. There is preliminary evidence supporting the use of symptom-limited aerobic exercise, targeted physical therapy and a collaborative approach that includes cognitive behavioural therapy. Management of patients with persistent symptoms is challenging and should occur in a multidisciplinary collaborative setting, with healthcare providers with experience in SRC.
Rifaximin reduces cirrhotic complications and prolongs overall survival in patients experiencing hepatic encephalopathy
Authors: S.H. Kang, J.-J. Yoo, J.-H. Lee, J.Y. Nam, Y. Chang, H. Cho, Y.Y. Cho, Y.B. Lee, E.J. Cho, S.J. Yu, J.S. Lee, Y.J. Kim, J.-H. Yoon
Journal: Journal of Hepatology (2017)
US Representatives vote to repeal Affordable Care Act
Authors: Michael McCarthy
Journal: BMJ (2017)

By a narrow 217 to 213 margin, the US House of Representatives passed legislation on 4 May that, should it become law, will repeal major provisions of the 2010 Affordable Care Act. No Democrats voted for the legislation, and 20 Republicans voted against it.

The bill, called the American Health Care Act, now goes to the Senate where most observers believe it stands little chance of passage in its current form. Republicans have only a three vote majority, and several key Republican moderates have already said that the bill will cause too many of their constituents to lose coverage. Of particular concern are provisions that cut funding for Medicaid and phase out its expansion—a provision of the Affordable Care Act that is credited with increasing the number of people with insurance by more than 14 million.

However, at a celebratory gathering at the White House, President Donald Trump said …
Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents.
Authors: Neil Love, Kenneth Carl Anderson, Keith Flaherty, Hagop M. Kantarjian, Thomas James Lynch, Joyce O'Shaughnessy, A. Oliver Sartor, Alan Paul Venook, Andrew David Zelenetz, Jonathan Moss, Gloria Kelly, Kathryn Ziel
Journal: Journal of Clinical Oncology (2013)

e17570 Background: The rapid pace of current oncology drug development has provided medical oncologists (MO) and patients with many additional treatment options, but minimal publicly accessible information exists on how new agents are incorporated into practice. Methods: From 12/15/2012 to 1/21/2013,100 US-based MO were recruited to complete a survey assessing the diseases they treat and their prescribing experiences with 20 oncologic drugs approved between 9/2009 and 11/2012. MO who manage related cancers were asked to self-report on a 3-point scale their comfort level using these agents. A modest honorarium was provided. Results: See Table. MO generally had limited clinical experience, even with drugs used in common cancers. Multiple clinical and logistical factors were cited for not using agents. For only 4 of the drugs did more than half of MO self-rate their prescribing confidence as 3 (very confident). Conclusions: Variation in MO use of recently approved drugs is multifactorial, and the suboptimal comfort levels reported here may reflect the natural evolution of clinical experience over time. Further research is needed to determine if an improved information infrastructure would better and more rapidly prepare MO to incorporate these and other soon-to-be-approved agents into practice. [Table: see text]
Socioeconomic status and susceptibility to alcohol-related harm
Authors: Wayne Hall
Journal: The Lancet Public Health (2017)

Alcohol is a major contributor to the global burden of disease,1 adding to inequities in health2 and life expectancy and affecting disproportionately drinkers of lower socioeconomic status. Analyses of population data for alcohol use and harm in different socioeconomic groups have noted consistently that the same patterns of alcohol consumption cause more harm in drinkers of lower than higher socioeconomic status.3
Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)
Authors: Margaretha G M Roemer, Azra H. Ligon, Andreas Engert, Anas Younes, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Stephen Ansell, Philippe Armand, Michelle A Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B. Cohen, Graham P. Collins, Kerry J Savage, Marek Trneny, Donna S. Neuberg, Robert A Redd, Benedetto Farsaci, Kazunobu Kato, Anne Sumbul, Scott J Rodig, Margaret A. Shipp
Journal: Blood (2016)
Hepatitis B virus basal core promotor variants become selected in serum hepatitis B virus DNA but not in hepatitis B virus RNA genome in patients responding to treatment with peginterferon-alfa 2a (PEG-IFNα)
Authors: M. Grossmann, D. Deichsel, V. Pavlovic, H. He, C. Wat, C. Hahn, T. Berg, F. Van Boemmel
Journal: Journal of Hepatology (2017)
Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients
Authors: A. Feldman, L. Denkmayr, M. Strasser, S. Ruhaltinger, G. Strebinger, U. Huber-Schönauer, D. Niederseer, L. Stechemesser, S. Zandanell, B. Paulweber, C. Datz, E. Aigner
Journal: Journal of Hepatology (2017)
Anti-steatotic effects in conjunction with lowering of PNPLA3 mRNA exerted by LXR inverse agonists in human hepatocytes and in rodent models of non-alcoholic fatty liver disease
Authors: C. Kremoser, E. Hambruch, C. Gege, U. Deuschle, O. Kinzel, D.H. Krol, M. Albers, M. Birkel
Journal: Journal of Hepatology (2017)
Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir
Authors: H. Wedemeyer, A.J. Hui, W. Sukeepaisarnjaroen, P. Tangkijvanich, W.W. Su, G.E.G. Nieto, P. Gineste, J. Nitcheu, S. Crabé, S. Stepien, M. Cornberg, C. Trépo
Journal: Journal of Hepatology (2017)
Avoidance of Allogeneic Blood Transfusions by Treatment With Epoetin Beta (Recombinant Human Erythropoietin) in Patients Undergoing Open-Heart Surgery
Authors: Olaf Sowade, Harry Warnke, Paul Scigalla, Birgit Sowade, Werner Franke, Diethelm Messinger, Johann Gross
Journal: Blood (1997)
Anxiety, depression and perceived sporting performance among professional cricket players
Authors: M Sahni, G Bhogal
Journal: British Journal of Sports Medicine (2017)

Mental health in sport is a hard-hitting topic that is frequently the subject of news coverage and increasingly a theme for avid research. Some suggest that cricketers, participating in a game unique in its statistical analysis of individual performance, prolonged periods of play away from home and extended solitary game time to reflect on errors, may be especially prone to developing depression. This hypothesis is supported by a higher rate of suicide among male Test cricketers when compared with the UK male general population.
Phase II AIDS Malignancy Consortium trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS).
Authors: H. B. Koon, K. Honda, J. Y. Lee, A. Noy
Journal: Journal of Clinical Oncology (2011)

10028 Background: KS is a disease of multi-focal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8). KSHV infected cells demonstate activation of the c-kit and platelet derived growth factor (PDGF) receptors. Partial KS regression in 5/10 patients was observed in a pilot study using the c-kit/PDGF-R inhibitor imatinib (Novartis Pharmaceuticals) suggesting this agent has activity in KS. Methods: The primary objective was to estimate the response rate in AIDS-related KS. Secondary objectives included investigation biomarkers of response and imatinib pharmacokinetics in patients on cART. Plasma concentrations of CCL5, IFNg, IL-6 and FGF-b were measured. Patients were treated with imatinib 400mg/day orally for up to 12 months with the option to dose escalate to 600mg/day at 3 months if disease was stable. Results: Thirty patients were treated at 12 AMC sites. Median CD4 count was 263 (19-819). 79% had undetectable HIV RNA. Ten (33.3%) showed partial response, 6 (20%) had stable disease and 7 (23.3%) showed KS progression. Nine patients completed 52 weeks of imatinib and the median treatment duration was 22.5 weeks (0.3-52.7). Only 5 patients (16.7%) discontinued therapy due to adverse events including grade 3 hypophosphatemia (2) allergic reaction (1), cellulitis (1), depression (1) and grade 4 elevation of CK (1). Pharmacokinetic analysis of the AUC ratios demonstrated that actual imatinib AUC levels were significantly higher than predicted (P=0.036), but there was no difference between actual and predicted AUC for the active metabolite (P=0.441), suggesting the anti-retroviral regimens influenced imatinib metabolism. Levels of CCL5, IFNg, IL-6 and FGF-b correlated with response in a pilot study; however, none of these growth factors predicted response in this larger study. Conclusions: Imatinib has activity in AIDS-related Kaposi's sarcoma. The potential interactions with antiretroviral drugs did not correlate with increased toxicity. Thirty percent of patients showed long-term clinical benefit and remained on imatinib for the entire year. These results suggest this regimen is well tolerated and may be an alternative to cytotoxic chemotherapy for some patients with AIDS-related KS.
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
Authors: Michael C. Heinrich, Jonathan A. Fletcher, Rana Anjum, Cesar Serrano-Garcia, Sadanand Vodala, Sebastian Bauer, Ajia Town, Meijun Zhu, Yaoyu Ning, Grant Eilers, Diana Griffith, Janice Patterson, Arin McKinley, Frank Y Wang, Andrew P Garner, Victor M. Rivera
Journal: Journal of Clinical Oncology (2013)

10509 Background: Ponatinib (PO) is a multi-targeted tyrosine kinase inhibitor with potent pan-BCR-ABL activity that has recently been approved for treatment of CML and Ph + ALL. PO also inhibits the kinase activity of KIT. Approximately 80% of gastrointestinal stromal tumors (GIST) contain primary activating KIT mutations, the majority of which cluster in exon 11. Imatinib (IM) is approved for the 1 st line treatment of GIST; however, patients frequently relapse due to the acquisition of secondary resistance mutations located in either the KIT ATP-binding pocket or the activation (A) loop. Sunitinib (SU) is approved for 2 nd line treatment of GIST but does not effectively inhibit A-loop mutants. Here we explored the activity of PO against major primary and secondary KIT mutants found in GIST. Methods: The drug sensitivity of KIT mutants was determined using engineered Ba/F3 cells harboring mutant forms of KIT exon 11 with or without ATP binding pocket or A-loop mutations. The abilities of PO, IM, SU, and regorafenib (RE) to inhibit viability and/or KIT kinase activity were compared using this system as well as an isogenic CHO cell system. We also profiled these same drugs using a panel of GIST cell lines, including cell lines with IM-resistant secondary KIT mutations. Results: In all in vitro systems, PO potently inhibited KIT exon 11 mutant kinases, with an IC50 of &lt; 30 nM. PO also potently inhibited a range of secondary KIT mutants, including multiple A-loop mutant kinases. PO induced substantial tumor regression in Ba/F3 tumor models expressing a KIT exon 11 mutant with or without an A-loop mutation (D816H). Using GIST cell lines, PO inhibited the viability of those harboring primary KIT exon 11 and secondary resistance mutations more effectively than IM, SU, and RE. Importantly, in patients dosed once daily with 45 mg ponatinib, plasma concentrations achieved are predicted to lead to inhibition of all KIT mutants tested with the possible exception of V654A. Conclusions: PO potently inhibits the majority of clinically relevant KIT mutant kinases and has a broader spectrum of activity compared to IM, SU, or RE. Based on these data, a phase 2 study of PO in drug-resistant GIST is being initiated.
Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors
Authors: T. Pilot-Matias, P. Krishnan, G. Schnell, R. Tripathi, J. Beyer, T. Reisch, M. Irvin, T. Dekhtyar, T. Ng, Y. Lei, A. Asatryan, F. Mensa, C. Collins
Journal: Journal of Hepatology (2017)
The pro-inflammatory CD161+CD4+ T cells were recruited to liver through C-X-C motif chemokine receptor 6 (CXCR6)-C-X-C motif chemokine ligand 16 (CXCL16) and CX3CR1-CX3CL1 axes during chronic hepatitis B
Authors: L.-S. Cheng, S.-Q. Wang, W. Jiang
Journal: Journal of Hepatology (2017)
Development of de novo and recurrent hepatocellular carcinoma in a Romanian cohort of compensated HCV genotype 1b liver cirrhosis with SVR after 3D and ribavirin therapy
Authors: L. Gheorghe, M.C.S. Iacob, M. Grasu, R. Dumitru, R. Iacob, I. Lupescu, C. Gheorghe
Journal: Journal of Hepatology (2017)
From the authors:
Authors: N. Hart, J. Moxham, M.I. Polkey
Journal: European Respiratory Journal (2004)

We would like to thank A. McConnell and colleagues for their interest in our editorial; such pieces are intended to be thought provoking and it seems that we have achieved this goal. We should initially like to observe that one of us (M.I. Polkey), as associate editor, handled and supported the publication of P. Weiner's paper. We do not think this is evidence of “vehement opposition” to inspiratory muscle training. Nevertheless, even if, as A. McConnell and colleagues argue, the therapy is of unequivocal benefit, this, in our view, makes understanding the basic mechanisms of even greater importance. In fact, some scepticism with regard to inspiratory muscle training is supported by a recent …
iPLA2beta protects aged male mice from liver fibrosis and intestinal atrophy by modulating phospholipid and enterohepatic bile acid metabolism
Authors: L. Jiao, H. Gan-Schreier, X. Zhu, W. Wei, S. Tuma-Kellner, G. Liebisch, W. Stremmel, W. Chamulitrat
Journal: Journal of Hepatology (2017)
Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: Interim analysis of expanded access program
Authors: K.K. Laktionov, L.V. Bolotina, V.V. Breder, A.S. Danilova, F.V. Moiseenko, T.P. Nikitina, R.V. Orlova, E.A. Filippova, S.A. Protsenko, T.I. Ionova
Journal: Annals of Oncology (2017)
IGF-1 receptor activation and intrinsic tamoxifen resistance in postmenopausal breast cancer patients.
Authors: Karin J. Beelen, Mark Opdam, Rutger H.T. Koornstra, Andrew D. Vincent, Jan Baptist Vermorken, Paul J. van Diest, Jelle Wesseling, Sabine C. Linn
Journal: Journal of Clinical Oncology (2014)

544 Background: Elevated insuline-like growth factor 1 receptor (IGF-1R) signaling activates the phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways and results in hormone indepedent cell growth in vitro, rendering cells resistant to anti-estrogens. The clinical validity of IGF-1R signaling to predict resistance to adjuvant anti-estrogen therapy has not been well established.We tested the predictive value of IGF-1R activation to predict adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Methods: We collected primary tumor blocks from 563 ERα positive (stage I-III) postmenopausal patients who had been randomized between tamoxifen (1 to 3 years) vs. no adjuvant therapy (IKA trial). The median follow-up of patients without a recurrence event was 7.8 years. Immunohistochemistry was performed on a tissue microarray using monoclonal antibodies for IGF-1R and phosphorylated(p)-IGF-1R. Cytoplasmic p-IGF-1R and membranous IGF-1R intensity were scored (0-3). To assess IGF-1R activation the ratio p-IGF-1R/ IGF-1R was calculated. Multivariate Cox models including standard prognostic factors were used to assess hazard ratios (HRs) for recurrence free interval and the interaction between tamoxifen treatment and IGF-1R activation, using the median ratio as cutoff. In addition we tested the association between the ratio p-IGF-1R/ IGF-1R and downstream-activated proteins in the PI3K and MAPK pathways. Results: Patients with a tumor with a low p-IGF-1R/ IGF-1R ratio (≤ 0.5) derived significant benefit from tamoxifen (HR 0.41, p=0.001), while patients whose tumor did express a high ratio did not (HR=1.47, p=0.53), p for interaction 0.05. Significant positive associations were observed between the p-IGF-1R/ IGF-1R ratio and p-AKT, p-ERK1/2, p-mTOR and p-p70S6K. Conclusions: In postmenopausal primary breast cancer patients, IGF-1R activation is associated with downstream PI3K and MAPK pathway activation and intrinsic tamoxifen resistance. A potential benefit from IGF-1R inhibitors in these tamoxifen resistant patients would be interesting to explore.
Addition of (pegylated) interferon to entecavir increases response in treatment naïve HBeAg-positive patients with chronic hepatitis B
Authors: S. Liem, M.J. van Campenhout, H. Chi, W.P. Brouwer, Q. Xie, X. Qi, C. Liang, F. Tabak, B.E. Hansen, H.L. Janssen
Journal: Journal of Hepatology (2017)
Short-Course carbon-ion radiation therapy for hepatocellular carcinoma: a nationwide survey by Japan Carbon Ion Radiation Oncology Study Group (J-CROS 1504)
Authors: K. Shibuya, T. Ohno, K. Terashima, S. Toyama, H. Tsuji, T. Okimoto, Y. Shioyama, T. Kamada, T. Nakano
Journal: Journal of Hepatology (2017)
BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles
Authors: Loges Sonja, Bjorn T. Gjertsen, Michael Heuser, Jörg Chromik, Isabel Ben Batalla, Nuray Akyüz, David Micklem, Anthony Brown, Jim Lorens, Maxim Kebenko, Melanie Janning, Mascha Binder, Walter Fiedler, Jorge E. Cortes
Journal: Blood (2016)